Interleukin 37 Explained

Interleukin 37 (IL-37), also known as Interleukin-1 family member 7 (IL-1F7), is an anti-inflammatory cytokine important for the downregulation of pro-inflammatory cytokine production as well as the suppression of tumor cell growth.[1]

Gene location and structure

The IL-37 gene is in the human located on the long chromosome arm of chromosome 2. There has not been found any homolog gene in mice genome.[2] IL-37 undergoes alternative splicing with 5 different splice variants depending on which of the 6 possible exons are being expressed: IL-37a-e. IL-37b is the largest and most studied one; it shares the beta barrel structure that is spread within the interleukin-1 family.

Gene expression

IL-37a,b,c are being expressed in a variety of tissues - thymus, lung, colon, uterus, bone marrow. It is produced by immune cells, most of which are relevant to the immune inflammation response. Examples include natural killer cells, activated B lymphocytes, circulating blood monocytes, tissue macrophages, keratinocytes or epithelial cells.

Some IL-37 isoforms are tissue specific and have varying lengths depending on which exons are being expressed:

IL-37a is found in the brain. The isoform includes exons 3, 4, 5, and 6 and the isoform is 192 amino acids in length

IL-37b is found in the kidney, bone marrow, blood, skin, respiratory and urogenital tract. Exons 1, 2, 4, 5, and 6 are expressed and the isoform is 218 amino acids in length.

IL-37c is found in the heart, and contains exons 1, 2, 5, and 6 for a total amino acid length of 197.

IL-37d is found in the bone marrow and includes exons 1, 4, 5, and 6 for a total length of 197.

IL-37e is found in the testis and includes exons 1, 5, and 6 totaling 157 amino acids.

Function

The mechanism of IL-37 functions is still to be elucidated. Known functions of IL-37 include anti-inflammatory effects, tumor suppression, and antimicrobial responses. IL-37 acts intracellulary and extracellulary, classifying the cytokine as dual-function.

IL-37 synthesis

IL-37, similar to other members of the interleukin-1 family, is synthesized by blood monocytes in a precursor form and secreted into the cytoplasm in response to inflammatory signaling. Examples of relevant inflammatory signals include TLR agonists, IL-1β, or TGF-β.[3] Full maturation requires cleavage by Caspase-1.[4]

Immune system inhibition

IL-37 is known to have immunosuppression properties through two different binding mechanisms:

Interaction with IL-18 cell surface receptors - Intracellular IL-37 can be released from cells following necrosis or apoptosis. IL-37 has two similar amino acid residues with IL-18, and thus extracellular IL-37 can interact with IL-18 receptor (IL-18R) and co-receptor IL-1 receptor 8 (IL-1R8). The affinity of IL-37b to IL-18R alpha subunit is much lower compared to IL-18. IL-37b interacts with IL-18 binding protein (IL-18BP), that is an antagonist of IL-18. The binding of IL-37b enhances the IL-18BP functions and can upregulate anti-inflammatory signals.

Binding to SMAD3 receptor - Mature intracellular IL-37 can form functional complexes with phosphorylated or unphosphorylated Smad3,which can be transported to the cell nucleus. Nucleus IL-37 can have a direct inhibition function on the expression of pro-inflammatory cytokine gene transcription. Affected cytokines include IL-1β, IFN-γ, IL-6, and TNF-α.[5] [6]

Tumor-controlled expression

IL-37 functions are active at low IL-37 concentrations. Higher concentrations leads to inactivation via dimer formation. Experiments also show that certain cancer strains correspond to changes in IL-37 expression levels. Breast cancer and ovarian cancer are associated with elevated expression of IL-37. Colon cancer, lung cancer, Multiple Myeloma, and Hepatoma Carcinoma were correlated with decreased expression of IL-37 expression in affected areas.

See also

Further reading

Notes and References

  1. Wang L, Quan Y, Yue Y, Heng X, Che F . Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy . Oncology Letters . 15 . 4 . 4711–4719 . April 2018 . 29552110 . 5840652 . 10.3892/ol.2018.7982 .
  2. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA . IL-37 is a fundamental inhibitor of innate immunity . Nature Immunology . 11 . 11 . 1014–1022 . November 2010 . 20935647 . 3537119 . 10.1038/ni.1944 .
  3. Mei Y, Liu H . IL-37: An anti-inflammatory cytokine with antitumor functions . Cancer Reports . 2 . 2 . e1151 . April 2019 . 32935478 . 7941439 . 10.1002/cnr2.1151 .
  4. Pan Y, Wen X, Hao D, Wang Y, Wang L, He G, Jiang X . The role of IL-37 in skin and connective tissue diseases . Biomedicine & Pharmacotherapy . 122 . 109705 . February 2020 . 31918276 . 10.1016/j.biopha.2019.109705 . free .
  5. Jia H, Liu J, Han B . Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases . BioMed Research International . 2018 . 3058640 . 2018-04-01 . 29805973 . 5899839 . 10.1155/2018/3058640 . free .
  6. Bello RO, Chin VK, Abd Rachman Isnadi MF, Abd Majid R, Atmadini Abdullah M, Lee TY, Amiruddin Zakaria Z, Hussain MK, Basir R . 6 . The Role, Involvement and Function(s) of Interleukin-35 and Interleukin-37 in Disease Pathogenesis . International Journal of Molecular Sciences . 19 . 4 . 1149 . April 2018 . 29641433 . 10.3390/ijms19041149 . 5979316 . free .